Regeneron Tagged Sell at $808; Dupixent Boom Can't Offset Eylea Erosion and LOE Risks

What happened

Regeneron's stock traded around $808 ahead of Q3 2026 earnings, and Seeking Alpha published a sell rating with a fair value near $675, implying 16.4% downside. The article acknowledges Dupixent's robust growth but flags the 2031 patent expiration and biosimilar threats as capping long-term value. It also notes that EYLEA HD growth is partially offsetting declines in legacy EYLEA, but the franchise's overall erosion remains a key concern. This contrasts with the earlier DeepValue master report from February 2026, which rated REGN a potential buy at $774 with an attractive entry of $720 and trim above $900, based on near-term catalysts like EYLEA HD demand and pre-filled syringe approval. The new sell rating suggests that even if those catalysts pan out, the market may be pricing in more than fair value, and the long-term risks are underappreciated.

Implication

The clash between the earlier potential-buy call and the new sell rating suggests that the upside from near-term EYLEA HD stabilization may be limited relative to long-term headwinds. The $808 price is above the master report's attractive entry of $720 and close to its trim level, but the Seeking Alpha fair value of $675 is even lower, indicating a possible overshoot. If Q3 2026 earnings confirm EYLEA HD demand softness or biosimilar pressure, the stock could re-rate toward $675, while a stronger-than-expected Dupixent trajectory may only partially offset. The 2031 Dupixent patent expiration remains a structural overhang that will increasingly dominate valuation as the date approaches. Therefore, investors should consider tightening stop-losses or reducing exposure above $800, while waiting for a better entry near $675–$720 if the long-term thesis still holds.

Thesis delta

The latest Seeking Alpha analysis shifts the thesis from a catalyst-driven potential buy to a valuation-driven sell. Earlier, the DeepValue report saw upside to $830–$950 if EYLEA HD stabilized and Dupixent continued growing, but the new article argues that even that scenario is insufficient to justify $808 given the 2031 patent cliff. The key delta is that the market may be overestimating the durability of Dupixent's cash flows and underestimating franchise erosion and biosimilar risks.